IMVT

Immunovant Inc.

Price

$44.96

return (12m)

203.37%

p/e

-15.81

p/bv

11.57

DIVIDEND YIELD

0.00%

IMVT price

Immunovant

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment IMVT

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

13.11%

3 months

31.73%

1 year

203.37%

2 years

44.24%

5 years

472.74%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals IMVT

Valuation

P/E

-15.81

Sector -4.38

Industry -4.38

P/BV

11.57

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector -4.40

Industry -4.40

EV/EBITDA

-48.12

Sector -263.09

Industry -263.09

EV/EBIT

-48.09

Sector -702.90

Industry -702.90

P/EBITDA

-15.04

Sector -4.39

Industry -4.39

P/EBIT

-15.03

Sector -4.73

Industry -4.73

P/Total Assets

9.98

Sector 1.49

Industry 1.49

P/Net Current Assets

11.59

Sector -11.70

Industry -11.70

P/Working Capital

11.59

Sector -3.19

Industry -3.19

EPS

-2.61

Sector -2.14

Industry -2.14

BVPS

3.57

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

0.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

0.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

0.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-73.19%

Sector -65.14%

Industry -65.14%

ROA

-63.14%

Sector -65.53%

Industry -65.53%

ROIC

-4,058.55%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

7.27

Sector 2.90

Industry 2.90

Net Debt / EBITDA

4.98

Sector -6.07

Industry -6.07

Net Debt / EBIT

4.98

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.08

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.86

Sector 0.41

Industry 0.41

Liabilities/Assets

0.14

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

31.34%

Sector -

Industry -

Fundamentals IMVT

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
IMVT Immunovant Inc.	$44.96	194.63%	0.00%	-15.81	11.57	-73.19%	0.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

IMVT Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Immunovant

Immunovant Inc.

Average Investor10 user rating

4.0 (1 people)

United States

8 years

Founded: 2018

2019

Time since IPO - 7 years

68

Employees

Immunovant Inc. (United States) is listed on the Nasdaq and has a market capitalization of $8.51 billion, with shareholders equity totaling $735.39 million.

The company employs approximately 68 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Immunovant Inc. reported $- in revenue, generating net income of $-538.22 million.

Key financial metrics include a P/E ratio of -15.81, a price-to-book (P/B) ratio of 11.57, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker IMVT.

Market cap

$8.51 billion

Net worth

$735.39 million

$735,390,000.00

Assets

$852.49 million

$852,490,000.00

Total Shares Outstanding

206.00 million

206,000,000

Average Daily Trading Volume

$1.29 million

$1,286,194.02

Sector

Health Care

Industry

Biotechnology

IMVT

IMVT revenue and profits

Financial Results IMVT

DRAG THE FRAME TO SEE MORE DATA

IMVT cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Immunovant (IMVT) today?

A cotação de Immunovant (IMVT) hoje está em US$ 44.96, com uma variação de 203.37% em relação ao último ano. A cotação de Immunovant (IMVT) iniciou o ano negociando na casa dos US$ 25.42 e hoje está em US$ 44.96. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Immunovant (IMVT) e dados de ações do Ibovespa e mercados internacionais.

Quando Immunovant (IMVT) paga dividendos?

Immunovant (IMVT) não distribuiu dividendos no último ano.

Is Immunovant (IMVT) a good investment?

Atualmente, Immunovant (IMVT) está cotada a US$ 44.96, com um P/L de -15.81, representando um desvio de -1,431% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 203.37 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 203.37%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Immunovant (IMVT) stock?

Investir em ações de Immunovant (IMVT) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Immunovant (IMVT) yield today?

A rentabilidade de Immunovant (IMVT) foi de 13.11% no último mês, 203.37% no último ano e 472.74% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Immunovant (IMVT) hoje, o investimento total seria de US$ 4,496.00, com base na cotação atual de US$ 44.96.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 13,639.52
Em 5 anos: US$ 25,750.39
Em 10 anos: US$ 4,496.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

IMVT

Immunovant Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment IMVT

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING IMVT WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Immunovant

Immunovant Inc.

United States

8 years

2019

68

PROFIT X PRICE IMVT

Financial Results IMVT

IMVT cash flow

Asset, Revenue and Profit Growth - IMVT

IMVT balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions